Clinical Trial Search

Primary: Pharmacodynamic Effect: The Platelet Inhibition Effect of Clopidogrel at the Various Times on Day 7 (0-24 Hours) (at Steady State) — 1853.58; 1892.84 percent…

Primary: Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential…

Primary: Number of Participants With Adverse Events — 100; 42 participants

Primary: Changes of Neurological Scores for Baseline — -0.158; 0; 2.208; -0.766 units on a scale — p=0.343

Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001

Primary: Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin — -0.88; -0.27 Percent of…

Primary: Time of Intubation — 41.22; 37.62; 27.80 seconds

Primary: Number of CD25 Pos/FoxP3 Positive Cells — 12.7; 14.6 cells per High power field (HPF)

Primary: Percentage BOLD (Blood-oxygen-level Dependent Contrast Imaging) Signal From Baseline at 2 Weeks — 3; 2 percentage change of BOLD

Primary: Change in Systolic Blood Pressure During the Night — 154; 162; 157; 158 mm Hg — p=0.036

Primary: Change From Baseline in Serum Phosphorus at Day 22 (Genz-644470 vs Placebo) — -0.0; -0.6; -1.2; -1.8 mg/dL — p=0.0249

Primary: Progression-free Survival (PFS) — 46.4 weeks

Primary: Tumor Response — 10 participants

Primary: Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication — 83.3; 10.0 percentage of participants

Primary: Flow-mediated Dilation (FMD) — 4.89; 4.81 percent change in diameter